Emerging preclinical research suggests that GLP-1 receptor agonists may directly inhibit the proliferation of neoplastic cells, promote programmed cell death (apoptosis), and reduce metastatic potential through the regulation of matrix metalloproteinases and their inhibitors
This compound has gained significant attention within the scientific community for its unique receptor activity profile and ongoing research interest in controlled laboratory settings
Existing PAs end 12/31/2025
CJC-1131, a long acting GLP-1 analog, safely normalizes post-prandial glucose excursion and fasting glycemia in type 2 diabetes mellitus [abstract]
Glucagon Receptor Agonism Increases energy expenditure Promotes lipolysis and fat oxidation Reduces liver fat accumulation Improves insulin sensitivity over time Together, these mechanisms help the body burn more fat, reduce blood sugar, and restore metabolic balance
However, the 12mg maintenance dose still requires multiple draws or a 1mL+ syringe
